News
Showing all blog posts in the News category.
news
TRIUMPH-1 Phase 3 Results: Retatrutide Delivers 28.3% Weight Loss in 2,339-Patient Obesity Trial
Eli Lilly's pivotal TRIUMPH-1 Phase 3 trial of retatrutide (May 21, 2026) reported 28.3% mean weight loss at 12 mg over 80 weeks, with 45.3% of participants losing 30%+ of body weight. Full results, safety profile, and what it means for the regulatory timeline.
| 7 min
news
Retatrutide in the Context of the GLP-1 Revolution
How retatrutide fits into the broader GLP-1 revolution that is transforming metabolic medicine, and what the competitive landscape means for the future of obesity and diabetes treatment.
| 5 min